Could Radiation Therapy Alone Replace Surgery for Some Breast Cancer Patients?
A groundbreaking Phase 2 trial presents compelling evidence that a subset of patients with early-stage, hormone receptor-positive (HR+) breast cancer may safely forgo surgery after receiving targeted radiation therapy combined with endocrine treatment. The findings, presented at the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress, could redefine treatment paradigms for women seeking less invasive options.
Why This Study Matters
For decades, the standard of care for early-stage breast cancer has centered on surgery—either lumpectomy or mastectomy—followed by additional treatments like radiation or hormone therapy. However, emerging research suggests that highly targeted radiation therapy, delivered with precision and in combination with endocrine therapy, may achieve complete tumor eradication in select patients without the need for surgery. This approach could offer significant benefits, including reduced recovery time, fewer complications, and improved quality of life for those who prefer to avoid operative interventions.
As Dr. Simona Shaitelman, Professor of Breast Radiation Oncology at The University of Texas MD Anderson Cancer Center, noted during the ESTRO presentation: “Advances in radiation delivery are opening the door to entirely new, non-operative approaches that many patients have been asking about.”
Study Design and Eligibility Criteria
The trial enrolled 20 patients with a median age of 71, all of whom met the following criteria:
- Stage 1, unicentric (single-tumor) breast cancer
- Hormone receptor-positive (HR+), HER2-negative
- Favorable tumor biology (grade 1 or 2)
Participants underwent a three-month course of endocrine therapy (e.g., tamoxifen or aromatase inhibitors) to shrink tumors before receiving ablative radiation therapy—a highly concentrated, five-fraction regimen designed to maximize tumor destruction while minimizing healthy tissue exposure.
Remarkable Outcomes: Complete Tumor Eradication in Over Half of Patients
Of the 20 patients, 19 underwent post-treatment biopsies, revealing:
- 10 patients (53%) achieved a pathologic complete response (PCR)—meaning no detectable cancer cells remained in the breast tissue.
- Among those with PCR, no breast cancer-related deaths occurred during a median follow-up of over three years.
- Tumor control rate was 100% in patients who avoided surgery.
The study also identified three key biomarkers associated with higher likelihood of complete response:
- Smaller tumor size after initial endocrine therapy
- Greater tumor volume reduction before radiation
- Higher estrogen receptor (ER) expression in tumors
“This isn’t just about reducing treatment intensity—it’s about rethinking the entire sequence of care. By delivering radiation before surgery, we’re taking advantage of the tumor’s heightened sensitivity after endocrine therapy, which can make it far more susceptible to radiation’s effects.”
How Does This Approach Work?
Traditional breast cancer treatment often follows a “surgery-first” model, where tumors are removed before radiation or hormone therapy. However, this trial explored a sequential, biology-driven approach:
- Endocrine Therapy First: Hormone-blocking drugs (e.g., tamoxifen) shrink tumors and make remaining cancer cells more susceptible to radiation.
- Targeted Radiation: Instead of the conventional 15–30 fractions, patients receive five high-dose fractions of radiation, delivered with advanced techniques like intensity-modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) to maximize precision.
- Monitoring and Follow-Up: Patients are closely monitored for recurrence, with biopsies confirming tumor eradication in responders.
This method leverages the synergistic effect of combining endocrine therapy’s tumor-shrinking properties with radiation’s ability to destroy remaining cancer cells at a molecular level.
Who Might Benefit from This Approach?
While the results are promising, this treatment is not a one-size-fits-all solution. Current evidence suggests it may be most suitable for:
✅ Ideal Candidates
- Women aged 65+ with low-risk, HR+, HER2-negative breast cancer.
- Patients with small, unicentric tumors (single tumor, not multifocal).
- Those who prefer to avoid surgery due to medical, psychological, or lifestyle reasons.
- Individuals with great performance status and no contraindications to radiation or endocrine therapy.
❌ Current Limitations
- Not yet approved for younger patients or those with higher-risk tumors (e.g., triple-negative or HER2-positive).
- Requires strict eligibility criteria and access to advanced radiation technology.
- Long-term data beyond three years are still limited.
Vital Note: This approach is experimental and currently only available through clinical trials. Patients should consult their oncologist to determine if they qualify.
Next Steps: Expanding Access and Research
The study’s authors emphasize that larger, multi-institutional trials are needed to validate these findings and refine patient selection. Dr. Shaitelman highlighted:
“Radiation therapy is widely accessible worldwide, yet its full potential as a definitive treatment for breast cancer hasn’t been fully explored. With over two million women diagnosed annually, we must rigorously study non-surgical options to meet the diverse needs and preferences of patients.”
Potential next steps include:
- Expanding trials to include younger patients and those with slightly higher-risk tumors.
- Developing biomarker-driven protocols to better predict which patients will respond.
- Evaluating quality-of-life outcomes compared to traditional surgery.
- Assessing cost-effectiveness and global accessibility.
Frequently Asked Questions
1. Is this treatment available now?
No. This approach is currently experimental and only offered through clinical trials. The Phase 2 results are promising, but larger studies are needed before it becomes standard practice.
2. Who is a good candidate?
Ideal candidates are likely postmenopausal women with early-stage, HR+, HER2-negative breast cancer and small, unicentric tumors. However, eligibility will depend on trial-specific criteria.
3. How does this compare to other de-escalation strategies?
Unlike traditional de-escalation (e.g., shorter hormone therapy or reduced radiation doses), this approach eliminates surgery entirely for responders. It aligns with broader trends in breast-conserving strategies but represents a more radical shift.
4. What are the risks?
Potential risks include:
- Tumor recurrence (though none were observed in this trial’s responders).
- Skin reactions or fatigue from radiation.
- Long-term side effects of endocrine therapy (e.g., bone loss, hot flashes).
Patients must weigh these against the risks of surgery (e.g., infection, scarring, lymphedema).
5. Could this replace surgery for most patients?
Unlikely in the near term. This approach is tailored to a specific subset of low-risk patients. Surgery remains the gold standard for most early-stage breast cancers, but research like this may lead to more personalized treatment pathways.
Expert Perspective: What This Means for the Future
Dr. Natalie Singh, Board-certified internist and MPH, offers her perspective:
“This study is a testament to how precision medicine is reshaping oncology. By combining advances in radiation technology with a deeper understanding of tumor biology, we’re moving toward treatments that are not only effective but also patient-centered. For women who face significant barriers to surgery—whether due to age, comorbidities, or personal preference—this could be a game-changer. However, it’s critical that patients do not pursue unproven alternatives. The key takeaway is that personalized, evidence-based options are on the horizon, and clinical trials remain the best way to access them.”
How to Get Involved
If you or a loved one are interested in exploring non-surgical options for breast cancer, consider:
- Discussing clinical trial eligibility with your oncologist.
- Visiting ClinicalTrials.gov to search for ongoing studies.
- Joining patient advocacy groups like the Breast Cancer Research Foundation for updates.